publication date: Sep. 6, 2019

NCI Trials

NCI Trials for September

The National Cancer Institute Cancer Therapy Evaluation Program approved the following clinical research studies last month. 

For further information, contact the principal investigator listed.

 

Phase I – 10217

A Phase 1b Biomarker-Driven Combination Trial of Copanlisib, Olaparib, and MEDI4736 (Durvalumab) in Patients with Advanced Solid Tumors

University of Texas MD Anderson Cancer Center LAO

Yap, Timothy Anthony

(713) 563-1784

 

Phase II – 10220

A Phase II Basket Trial of Glutaminase Inhibitor (BeGIN) CB-839 HCl in Patients with NF1 Aberrations, NF1 Mutant Malignant Peripheral Nerve Sheath Tumors (MPNST), KEAP1/NRF2 and LKB1 Aberrant Tumors

University of Texas MD Anderson Cancer Center LAO

Subbiah, Vivek

(713) 563-0393

 

Phase II – 10266

A Phase 2 Study of MLN4924 (Pevonedistat) in Combination with Carboplatin and Paclitaxel in Advanced NSCLC Previously Treated with Immunotherapy

Rutgers University – Cancer Institute of New Jersey LAO

Leal, Ticiana A.

(608) 263-9063

 

Phase II – 10268

Randomized Phase II Trial of Topotecan Plus M6620 (VX-970) Vs. Topotecan Alone in Patients with Relapsed Small-Cell Lung Cancer

National Cancer Institute LAO

Thomas, Anish

(240) 614-6467

 

Phase II – A071701

Genomically-Guided Treatment Trial in Brain Metastases

Alliance for Clinical Trials in Oncology

Brastianos, Priscilla Kaliopi

(617) 643-1938

 

Phase II – EA2182

A Randomized Phase II Study of De-Intensified ChemoRadiation for Early-Stage Anal Squamous Cell Carcinoma (DECREASE)

Continue reading NCI Trials for September 2019

To access this members-only content, please log in.
Institutional subscribers, please log in with your IP.
If you're not a subscriber why not join today?
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.
Click here to join.

Copyright (c) 2019 The Cancer Letter Inc.